Chickenpox Vaccination Program: Pharmacies Involved
- The UK government announced on april 25, 2024, that chickenpox vaccination will be added to the routine childhood immunisation schedule in England, starting September 2024.
- For decades, the UK has not routinely vaccinated against chickenpox, unlike many other European countries and the United States.
- The vaccine will be offered as part of the routine childhood immunisation schedule, likely administered in two doses.
“`html
Chickenpox Vaccine to be Added to NHS Childhood Immunisation Schedule
What Happened?
The UK government announced on april 25, 2024, that chickenpox vaccination will be added to the routine childhood immunisation schedule in England, starting September 2024. This marks a meaningful shift in public health policy, aiming to reduce severe complications and hospitalisations associated with the highly contagious varicella-zoster virus.
Why the Change?
For decades, the UK has not routinely vaccinated against chickenpox, unlike many other European countries and the United States. The rationale behind this decision historically centered on the belief that widespread natural immunity offered sufficient protection and that vaccination could possibly increase the risk of shingles in older adults. However, recent evidence and changing circumstances have prompted a reevaluation of this approach.
Key factors driving the change include:
- High complication rates: While generally mild, chickenpox can lead to serious complications like bacterial skin infections, pneumonia, and encephalitis, particularly in vulnerable individuals.
- Disruption to education: Chickenpox outbreaks frequently cause school closures and absenteeism.
- inequities in access: Currently, only children at higher risk (e.g., those with weakened immune systems) are offered the vaccine privately, creating health inequalities.
- Shingles concerns addressed: Research suggests the risk of shingles following chickenpox vaccination is lower than previously thought.
Who Will Be Vaccinated and How?
The vaccine will be offered as part of the routine childhood immunisation schedule, likely administered in two doses. The Joint Committee on Vaccination and Immunisation (JCVI) recommends offering the vaccine to all one-year-olds. The exact implementation details, including the specific vaccine used and the delivery mechanism (e.g., GP surgeries, schools), are still being finalised by NHS England.
Pharmacies are likely
to be involved in providing the chickenpox vaccination program, according to reports from The Pharmaceutical Journal. This would expand the role of community pharmacies in public health initiatives and increase access to vaccination services.
| Age | Vaccination Schedule |
|---|---|
| 1 year old | First dose of chickenpox vaccine |
| 2 years old | Second dose of chickenpox vaccine (likely) |
Impact and Potential Challenges
The introduction of a chickenpox vaccine is expected to significantly reduce the incidence of the disease and its associated complications. It will also alleviate pressure on the NHS by reducing hospital admissions and GP appointments. however, challenges remain.
- Vaccine supply: Ensuring a sufficient supply of the vaccine to meet demand will be crucial.
- Public uptake: Maintaining high vaccination rates is essential to achieve herd immunity and maximise the benefits of the program. Addressing vaccine hesitancy will be important.
- Shingles monitoring: Ongoing monitoring of shingles incidence will be necessary to assess the long-term impact of the vaccination program.
Timeline of Key Events
- April 25, 2024: UK government announces chickenpox vaccine will be added to the NHS childhood immunisation schedule.
- September 2024: expected start date for the vaccination program.
- Ongoing: NHS england finalises implementation details and vaccine procurement.
Frequently Asked questions (FAQs)
- Is the chickenpox vaccine safe?
- Yes, the chickenpox vaccine is generally considered safe and effective. Like all vaccines, it can cause mild side effects, such as soreness at the injection site and a mild rash. Serious side effects are rare.